Log in
NASDAQ:ACST

Acasti Pharma Stock Forecast, Price & News

$0.24
-0.04 (-14.41 %)
(As of 09/22/2020 12:00 AM ET)
Add
Compare
Today's Range
$0.23
Now: $0.24
$0.25
50-Day Range
$0.19
MA: $0.51
$0.81
52-Week Range
$0.18
Now: $0.24
$3.08
Volume13.74 million shs
Average Volume3.95 million shs
Market Capitalization$23.02 million
P/E RatioN/A
Dividend YieldN/A
Beta1.91
Acasti Pharma Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of prescription drugs for the treatment of cardiovascular diseases. Its lead product candidate is CaPre, an omega-3 phospholipid therapeutic that is in Phase III clinical trial to treat patients with hypertriglyceridemia. The company was incorporated in 2002 and is headquartered in Laval, Canada.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 4.2Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.51 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ACST
CUSIPN/A
Phone45-0686-4555

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$0.14 per share

Profitability

Net Income$-25,510,000.00

Miscellaneous

Employees28
Market Cap$23.02 million
Next Earnings Date11/11/2020 (Estimated)
OptionableNot Optionable
$0.24
-0.04 (-14.41 %)
(As of 09/22/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive ACST News and Ratings via Email

Sign-up to receive the latest news and ratings for ACST and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Acasti Pharma (NASDAQ:ACST) Frequently Asked Questions

How has Acasti Pharma's stock been impacted by COVID-19?

Acasti Pharma's stock was trading at $0.3849 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, ACST stock has decreased by 38.3% and is now trading at $0.2376.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Acasti Pharma?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Acasti Pharma in the last year. There are currently 3 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold."
View analyst ratings for Acasti Pharma
.

When is Acasti Pharma's next earnings date?

Acasti Pharma is scheduled to release its next quarterly earnings announcement on Wednesday, November 11th 2020.
View our earnings forecast for Acasti Pharma
.

How were Acasti Pharma's earnings last quarter?

Acasti Pharma Inc (NASDAQ:ACST) issued its earnings results on Thursday, August, 13th. The biopharmaceutical company reported ($0.05) EPS for the quarter, topping the consensus estimate of ($0.06) by $0.01.
View Acasti Pharma's earnings history
.

What price target have analysts set for ACST?

5 brokers have issued 12 month target prices for Acasti Pharma's shares. Their forecasts range from $0.50 to $7.00. On average, they anticipate Acasti Pharma's stock price to reach $2.81 in the next twelve months. This suggests a possible upside of 1,082.7% from the stock's current price.
View analysts' price targets for Acasti Pharma
.

Are investors shorting Acasti Pharma?

Acasti Pharma saw a increase in short interest during the month of August. As of August 31st, there was short interest totaling 451,800 shares, an increase of 87.9% from the August 15th total of 240,500 shares. Based on an average trading volume of 4,900,000 shares, the days-to-cover ratio is presently 0.1 days. Currently, 0.5% of the company's stock are sold short.
View Acasti Pharma's Short Interest
.

Who are some of Acasti Pharma's key competitors?

What other stocks do shareholders of Acasti Pharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Acasti Pharma investors own include Matinas BioPharma (MTNB), SCYNEXIS (SCYX), Outlook Therapeutics (OTLK), Heat Biologics (HTBX), Sorrento Therapeutics (SRNE), ADMA Biologics (ADMA), BioNano Genomics (BNGO), KushCo (KSHB), AEterna Zentaris (AEZS) and Dynavax Technologies (DVAX).

Who are Acasti Pharma's key executives?

Acasti Pharma's management team includes the following people:
  • Ms. Janelle D' Alvise, Pres, CEO, Corp. Sec. & Director
  • Dr. Pierre Lemieux, Co-Founder and COO & Chief Scientific Officer
  • Mr. Jean-François Boily, VP of Fin.
  • Mr. Brian James Groch, Chief Commercial Officer (Age 53)

What is Acasti Pharma's stock symbol?

Acasti Pharma trades on the NASDAQ under the ticker symbol "ACST."

Who are Acasti Pharma's major shareholders?

Acasti Pharma's stock is owned by many different retail and institutional investors. Top institutional shareholders include Virtu Financial LLC (0.28%).
View institutional ownership trends for Acasti Pharma
.

Which institutional investors are buying Acasti Pharma stock?

ACST stock was acquired by a variety of institutional investors in the last quarter, including Virtu Financial LLC.
View insider buying and selling activity for Acasti Pharma
.

How do I buy shares of Acasti Pharma?

Shares of ACST can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Acasti Pharma's stock price today?

One share of ACST stock can currently be purchased for approximately $0.24.

How big of a company is Acasti Pharma?

Acasti Pharma has a market capitalization of $23.02 million. The biopharmaceutical company earns $-25,510,000.00 in net income (profit) each year or ($0.23) on an earnings per share basis. Acasti Pharma employs 28 workers across the globe.

What is Acasti Pharma's official website?

The official website for Acasti Pharma is www.acastipharma.com.

How can I contact Acasti Pharma?

Acasti Pharma's mailing address is 3009 BOUL. DE LA CONCORDE EAST SUITE 102, LAVAL A8, H7E 2B5. The biopharmaceutical company can be reached via phone at 45-0686-4555 or via email at [email protected]

This page was last updated on 9/23/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.